Dianthus Therapeutics earnings were -$100.7M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest DNTH earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$29.5M, up 3.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, DNTH reported annual earnings of -$85.0M, with 95.1% growth.
Dianthus Therapeutics Earnings Reports & History FAQ
What were Dianthus Therapeutics's earnings last quarter?
On DNTH's earnings call on Invalid Date, Dianthus Therapeutics (NASDAQ: DNTH) reported Q1 2025 earnings per share (EPS) of -$0.82, up 51.85% year over year. Total DNTH earnings for the quarter were -$29.51 million. In the same quarter last year, Dianthus Therapeutics's earnings per share (EPS) was -$0.54.
Is Dianthus Therapeutics profitable or losing money?
As of the last Dianthus Therapeutics earnings report, Dianthus Therapeutics is currently losing money. Dianthus Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$100.73 million, a 100.61% increase year over year.
What was DNTH's earnings growth in the past year?
As of Dianthus Therapeutics's earnings date in Invalid Date, Dianthus Therapeutics's earnings has grown year over year. DNTH earnings in the past year totalled -$100.73 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.